Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Acadia Pharmaceuticals (ACAD)

Acadia Q2 revenue rises 9% to $264.6 million; net income falls to $26.7 million

Mixed Impact 4 of 5 earnings Written later

Acadia Pharmaceuticals reported second-quarter 2025 total revenue of $264.6 million, up 9% from a year earlier, driven by growth in NUPLAZID and DAYBUE sales. Net income fell to $26.7 million, or $0.16 per share, because the effective tax rate rose, and the company raised the low end of its 2025 NUPLAZID sales guidance and its total revenue guidance.

Key points

  • Total revenue was $264.6 million, up 9% from $242.0 million in the second quarter of 2024.
  • Net income was $26.7 million, or $0.16 per diluted share, versus $33.4 million, or $0.20 per share, a year earlier.
  • Full-year 2025 total revenue guidance low end raised to $1.045 billion from $1.030 billion; NUPLAZID net sales guidance low end raised to $665 million; other guidance reiterated.
  • Top-line results from the COMPASS PWS Phase 3 study of ACP-101 are expected in early Q4 2025.

The filing

CompanyAcadia Pharmaceuticals (ACAD)
Form8-K, current report
Filed with the SECAug 6, 2025, 4:18 PM ET
Accession number0000950170-25-104092

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.